Activist shareholder aims to drive shakeup at immunotherapy firm IMV

Dr. Michael Gross, a disgruntled shareholder of immunotherapy specialist IMV (NSDQ:IMV), has launched an offensive intended to cause a leadership shakeup at the company.

Gross released a press release on June 1 announcing his plans to oust the company’s board chair Andy Sheldon and the chair of the board’s compensation committee, Julia Gregory.

The director must receive a majority of shareholder votes to retain his role. 

IMV will hold an annual general meeting on June 18. 

On June 4, Gross released a new press release stating that he had the support of approximately 25% of the outstanding common shares of IMV. 

Gross also stressed that he believes in IMV’s potential. 

An IMV spokesperson said the company’s management is aware of the concerned shareholder but had no further comment. The company has made recent changes to its board, installing Dr. Michael Kalos and Kyle Kuvalanka. Kalos is an expert in T-cell therapy and immunotherapy…

Read more
  • 0

Q&A: Why IMV’s DPX-Survivac shows promise in treating ovarian cancer

The biopharmaceutical company IMV (NSDQ:IMV) has recently revealed promising data related to its lead immunotherapy as a potential ovarian cancer treatment. In the Phase 2 DeCidE1 trial, the immunotherapy DPX-Survivac with intermittent low-dose cyclophosphamide showed durable anti-tumor activity in patients with recurrent, advanced ovarian cancer.

To learn more about DPX-Survivac’s potential, we reached out to IMV Chief Medical Officer Joanne Schindler. In the following interview, Schindler touches on the standard of care for treating recurrent ovarian cancer and provides an overview of the potential of the T-cell immunotherapy for treating a range of cancers.

Could you highlight some of the main challenges in treating recurrent ovarian cancer? 

Schindler: In recurrent ovarian cancer, platinum-based chemotherapy is the standard of care option for patients who have responded to prior platinum therapy and for whom recurrence was not rapid (e.g., >…

Read more
  • 0